论文部分内容阅读
目的探讨柔红霉素(DNR)和去甲氧柔红霉素(IDA)治疗急性白血的疗效和安全性。方法选择2012年1月至2014年9月间收治的急性白血病患者68例,采用随机数字表法分为对照组和观察组,每组34例。观察组患者采用IDA+阿糖胞苷或IDA+长春新碱+地塞米松化疗;对照组患者采用DNR+阿糖胞苷或DNR+长春新碱+地塞米松进行化疗。急性非淋巴细胞白血病治疗2个疗程,急性淋巴细胞白血病1个疗程后进行观察,主要观察指标为临床治疗效果及不良反应。结果观察组患者治疗后有效率为85.3%(29/34),高于对照组70.6%(24/34),差异有统计学意义(P<0.05)。观察组患者心脏毒副反应发生率为17.7%(6/34),低于对照组44.1%(6/34),差异有统计学意义(P<0.05)。结论 IDA治疗急性白血病具有较好的临床疗效,能够显著降低患者的不良反应,具有较高的安全性。
Objective To investigate the efficacy and safety of daunorubicin (DNR) and daunorubicin (IDA) in the treatment of acute leukemia. Methods Sixty-eight patients with acute leukemia who were admitted between January 2012 and September 2014 were randomly divided into control group and observation group with 34 cases in each group. Patients in the observation group received chemotherapy with IDA + cytarabine or IDA + vincristine + dexamethasone; patients in the control group received chemotherapy with DNR + cytarabine or DNR + vincristine + dexamethasone. Acute non-lymphocytic leukemia treatment of 2 courses of acute lymphoblastic leukemia after a course of observation, the main observation indicators for clinical treatment and adverse reactions. Results After treatment, the effective rate of the observation group was 85.3% (29/34), which was higher than that of the control group (70.6%, 24/34). The difference was statistically significant (P <0.05). The incidence of cardiac toxicity in observation group was 17.7% (6/34), which was lower than 44.1% (6/34) in control group (P <0.05). Conclusion IDA treatment of acute leukemia has a good clinical efficacy, can significantly reduce the adverse reactions in patients with high safety.